Brown Brothers Harriman & Co’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $647K | Buy |
9,600
+2,553
| +36% | +$170K | ﹤0.01% | 631 |
|
|
2026
Q1 | $443K | Buy |
7,047
+3,077
| +78% | +$214K | ﹤0.01% | 641 |
|
|
2025
Q4 | $263K | Buy |
3,970
+1,626
| +69% | +$105K | ﹤0.01% | 688 |
|
|
2025
Q3 | $158K | Buy |
2,344
+540
| +30% | +$42.7K | ﹤0.01% | 753 |
|
|
2025
Q2 | $157K | Sell |
1,804
-1,407
| -44% | -$110K | ﹤0.01% | 689 |
|
|
2025
Q1 | $219K | Hold |
3,211
| – | – | ﹤0.01% | 543 |
|
|
2024
Q4 | $250K | Sell |
3,211
-719
| -18% | -$53.2K | ﹤0.01% | 537 |
|
|
2024
Q3 | $263K | Sell |
3,930
-353
| -8% | -$29K | ﹤0.01% | 536 |
|
|
2024
Q2 | $486K | Sell |
4,283
-1,404
| -25% | -$178K | ﹤0.01% | 382 |
|
|
2024
Q1 | $789K | Buy |
5,687
+708
| +14% | +$89K | 0.01% | 304 |
|
|
2023
Q4 | $618K | Sell |
4,979
-390
| -7% | -$39.8K | 0.01% | 325 |
|
|
2023
Q3 | $501K | Buy |
5,369
+200
| +4% | +$22.5K | ﹤0.01% | 345 |
|
|
2023
Q2 | $664K | Buy |
5,169
+111
| +2% | +$13.4K | 0.01% | 294 |
|
|
2023
Q1 | $588K | Buy |
5,058
+85
| +2% | +$9.52K | ﹤0.01% | 315 |
|
|
2022
Q4 | $563K | Buy |
4,973
+2,944
| +145% | +$323K | ﹤0.01% | 300 |
|
|
2022
Q3 | $163K | Buy |
2,029
+237
| +13% | +$20.1K | ﹤0.01% | 502 |
|
|
2022
Q2 | $134K | Buy |
1,792
+28
| +2% | +$2.56K | ﹤0.01% | 538 |
|
|
2022
Q1 | $226K | Sell |
1,764
-200
| -10% | -$21.9K | ﹤0.01% | 484 |
|
|
2021
Q4 | $264K | Buy |
1,964
+96
| +5% | +$13.8K | ﹤0.01% | 433 |
|
|
2021
Q3 | $255K | Buy |
1,868
+104
| +6% | +$13.1K | ﹤0.01% | 406 |
|
|
2021
Q2 | $188K | Hold |
1,764
| – | – | ﹤0.01% | 457 |
|
|
2021
Q1 | $158K | Buy |
1,764
+1,064
| +152% | +$99.9K | ﹤0.01% | 462 |
|
|
2020
Q4 | $65K | Hold |
700
| – | – | ﹤0.01% | 623 |
|
|
2020
Q3 | $72K | Sell |
700
-1,200
| -63% | -$125K | ﹤0.01% | 530 |
|
|
2020
Q2 | $193K | Sell |
1,900
-96
| -5% | -$8.59K | ﹤0.01% | 379 |
|
|
2020
Q1 | $134K | Buy |
1,996
+96
| +5% | +$5.97K | ﹤0.01% | 409 |
|
|
2019
Q4 | $104K | Sell |
1,900
-124
| -6% | -$5.88K | ﹤0.01% | 558 |
|
|
2019
Q3 | $76K | Buy |
2,024
+100
| +5% | +$3.88K | ﹤0.01% | 579 |
|
|
2019
Q2 | $72K | Buy |
1,924
+1,224
| +175% | +$38.5K | ﹤0.01% | 540 |
|
|
2019
Q1 | $21K | Sell |
700
-900
| -56% | -$31.6K | ﹤0.01% | 718 |
|
|
2018
Q4 | $48K | Buy |
1,600
+400
| +33% | +$12.7K | ﹤0.01% | 518 |
|
|
2018
Q3 | $43K | Buy |
+1,200
| New | +$37.2K | ﹤0.01% | 536 |
|
|
2018
Q1 | – | Sell |
-240
| Closed | -$3K | – | 895 |
|
|
2017
Q4 | $3K | Buy |
+240
| New | +$3.12K | ﹤0.01% | 941 |
|
Other funds holding DXCM
Brown Brothers Harriman & Co's DXCM Position: Q2 2026 in Review
Brown Brothers Harriman & Co increased its DexCom (DXCM) stake by 36% in Q2 2026, buying an estimated $170K and bringing the position to 9,600 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #631.
Brown Brothers Harriman & Co first reported a position in DXCM in Q4 2017 and has held it in 33 quarters since. The position peaked at $789K in Q1 2024. 971 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.
- Brown Brothers Harriman & Co held 9,600 shares of DexCom worth $647K as of Q2 2026.
- Brown Brothers Harriman & Co bought 2,553 DexCom shares in Q2 2026, an estimated $170K.
- DexCom made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #631 holding.
- Brown Brothers Harriman & Co first reported a position in DexCom in Q4 2017 and has held it in 33 quarters since.
- Brown Brothers Harriman & Co's DexCom position peaked at $789K in Q1 2024.
- 971 funds tracked by Wall St. Rank held DexCom as of Q2 2026.
Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.